AVDL:NSD-Avadel Pharmaceuticals plc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 5.23

Change

0.00 (0.00)%

Market Cap

USD 0.30B

Volume

0.84M

Average Target Price

USD 14.17 (+170.87%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD7.45B 26.81 7.09
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.23B N/A N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.52B 870.20 73.37
CRON Cronos Group Inc

N/A

USD1.77B 2.44 N/A
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.51B 15.26 12.72
APHA Aphria Inc

N/A

USD1.22B 57.50 392.34
ATNX Athenex, Inc

N/A

USD1.14B N/A N/A
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.07B 9.18 5.84
PETQ PetIQ, Inc

N/A

USD0.91B 134.36 111.60
AMPH Amphastar Pharmaceuticals, Inc

N/A

USD0.86B 224.88 27.46

ETFs Containing AVDL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.73% 50% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.73% 50% F 27% F
Trailing 12 Months  
Capital Gain 23.06% 81% B- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.06% 81% B- 72% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 45.87% N/A N/A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.87% N/A N/A 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 167.16% N/A N/A 5% F
Risk Adjusted Return 27.44% N/A N/A 51% F
Market Capitalization 0.30B 56% F 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.59 55% F 48% F
Price/Book Ratio 1.60 69% D+ 58% F
Price / Cash Flow Ratio -7.95 80% B- 79% C+
EV/EBITDA 8.03 73% C 72% C-
Management Effectiveness  
Return on Equity 22.40% 98% A+ 92% A-
Return on Invested Capital -17.77% 58% F 29% F
Return on Assets -4.22% 66% D 33% F
Debt to Equity Ratio -416.75% 78% C+ 98% A+
Technical Ratios  
Short Ratio 7.28 46% F 21% F
Short Percent N/A N/A N/A N/A N/A
Beta 1.28 56% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.